Mizuno, Hideaki
Chugai Pharmaceutical Co., Ltd. (Japan)
2 papers on CoChatORCID 0000-0002-7246-2576
Most cited papers
- Verified
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell
Cancer, Lipids, and MetabolismCancer-related Molecular Pathways
Cited by 865
- Verified
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., Sawada, N., Tsunoda, H., Shima, T., Miyawaki, K., et al. (2019) · Molecular Cancer Therapeutics
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 80
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free